Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457738 | 0.90 | KDM4E (0.42) | PDE10AKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3456163 | 0.89 | LMNA (0.37) | PDE10AKDM4ELMNATP53MAPT | |
| SCHEMBL3457066 | 0.81 | L3MBTL1 (0.44) | PDE10ALMNATP53MAPTL3MBTL1 | |
| SCHEMBL14498544 | 0.77 | CXCR2 (0.41) | CXCR2PDE10A | |
| SCHEMBL3456550 | 0.77 | PLA2G2A (0.39) | PDE10AKDM4EMAPTL3MBTL1MAOA | |
| SCHEMBL3457700 | 0.77 | APP (0.46) | KDM4ELMNATP53MAPTL3MBTL1 | |
| SCHEMBL14352265 | 0.76 | MAOA (0.42) | KDM4EKMT2AALDH1A1LMNATP53 | |
| SCHEMBL29219438 | 0.76 | KCNH2 (0.48) | PDE10AKDM4EALDH1A1RAB9AMAOA | |
| SCHEMBL3457404 | 0.76 | PLA2G2A (0.46) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL14498545 | 0.75 | CXCR2 (0.41) | CXCR2PDE10AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| CN-1951917-B | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2012-07-18 | — | — | CN | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| CN-1951917-A | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-04-25 | — | — | CN | disclosed |
| CN-1280275-C | Pyridone derivatives for the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | CN | disclosed |
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
| EP-1492787-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-1492533-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-01 | — | — | US | disclosed |
| CN-1479724-A | Pyridone derivatives for the treatment of atherosclerosis | ʷ��˿�������ȳ�ķ����˾ | 2004-03-03 | — | — | CN | disclosed |
| WO-2003086400-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087088-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326841-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SmithKline Beecham P.L.C. (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2003042206-A1 | PYRIDINONE AND PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002030904-A1 | PYRIDINONE DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | CXCR2 3318/4885PDE10A 1343/4885KDM4E 3486/4885 |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | CXCR2 735/4885PDE10A 2318/4885KDM4E 3738/4885 |
| US-20040063753-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLPBP, PLAA | CXCR2 3185/4885PDE10A 1273/4885KDM4E 3479/4885 |
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | PLA2G12A, PLA2G4B, PLA2G1B | CXCR2 1600/4885PDE10A 1725/4885KDM4E 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.